05.23.23 -- Multiple Myeloma: Using The Immune System For Better Patient Outcomes

Sterile fill operators are crucial in ensuring pharmaceutical products are contaminant-free and safe for use. Explore best practices for sterile fill operator gowning training, mobile cleanroom benefits, and more.

It’s no secret – COVID-19 changed things. Now, as the pharma supply chain settles into a new normal, executives are shifting focus to better identify reliable, resilient, and forward-thinking partners.

Reducing human intervention and manual processes in advanced therapy manufacturing is critical to improving a manufacturing paradigm, safeguarding quality, simplifying processes, and improving efficacy.

Learn about new data that highlights exciting uses for future immunotherapy studies.

Nano-plate-based dPCR is compared to ddPCR analyses for different types of AAV samples to demonstrate that the QIAcuity is a successful platform for AAV titering.

Developing and manufacturing viral vectors at scale requires scientific expertise, technological know-how, and a solid infrastructure — all facilitated by a successful tech transfer process.

From supply chain constraints to siloed data to characterization and development hurdles, the variables that can limit scale for advanced therapies are both diverse and profound.

Discover how in silico recreation can be a valuable tool for predicting the efficacy of new treatments.

Surmounting challenges related to AAV manufacturing and scale-up represent an important opportunity for the advanced therapeutics space; finding the right partner hinges on experience, expertise, and capacity.

Next generation drug products are more targeted and patient specific by nature causing batch sizes to be much smaller. This paradigm shift paves the way for more flexible manufacturing solutions.

Examine the benefits of considering quality attributes early in the drug lifecycle and how an experienced CDMO can offer flexible, comprehensive support along the full development to commercialization journey.

The clonality of Master Cell Banks (MCBs) for production cell lines is a key requirement in biotherapeutics manufacturing. Learn how new devices help optimize the cloning process.

Learn more about oligo workflows and solutions for oligonucleotide process development, from scalable oligo synthesis to cleavage and deprotection, purification, and buffer exchange.

This panel discussion highlights technical and regulatory hurdles associated with development and manufacturing steps and strategies and solutions to facilitate development through commercialization.